To the full analysis
Viatris stock: growth
VTRSViatris reported $14.3B in revenue for fiscal 2025, down 3% on the prior year, up 3.7% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
13.7%
per year from 2005 to 2025, per share 4.3%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
10.1%
per year from 2005 to 2025, per share 1%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2005 | |
|---|---|---|---|
| Revenue | 3.7% | 4.3% | 13.7% |
| Revenue per share | −9.3% | −4.3% | 4.3% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | 28.6% | 1.6% | 10.1% |
| Free cash flow per share | 12.6% | −6.7% | 1.0% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2005 | $1.26B | $184.54M | $312.87M |
| 2007 | $2.91B | −$1.52B | $57.15M |
| 2008 | $5.14B | −$196.08M | $219.33M |
| 2009 | $5.09B | $232.57M | $450.67M |
| 2010 | $5.45B | $345.12M | $738.61M |
| 2011 | $6.13B | $536.81M | $440.58M |
| 2012 | $6.8B | $640.85M | $643.69M |
| 2013 | $6.91B | $623.7M | $772M |
| 2014 | $7.72B | $929.4M | $689.5M |
| 2015 | $9.43B | $847.6M | $1.65B |
| 2016 | $11.08B | $480M | $1.66B |
| 2017 | $11.91B | $696M | $1.79B |
| 2018 | $11.43B | $352.5M | $2.09B |
| 2019 | $11.5B | $16.8M | $1.4B |
| 2020 | $11.95B | −$669.9M | $550.6M |
| 2021 | $17.89B | −$1.27B | $2.51B |
| 2022 | $16.26B | $2.08B | $2.51B |
| 2023 | $15.43B | $54.7M | $2.33B |
| 2024 | $14.74B | −$634.2M | $1.98B |
| 2025 | $14.3B | −$3.51B | $1.94B |
Revenue by segment
How Viatris Inc. makes its money and how that has shifted. Names are as the company reports them.
- Brands64%
- Generics35%
- Other< 1%
“Other” combines smaller and former segments with revenue the company does not assign to a segment. Names as reported, with abbreviations spelled out for the largest companies.
Figures as a table
| 2021 | 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|---|
| Brands | $10.84B | $9.89B | $9.8B | $9.2B | $9.18B | 64.2% |
| Generics | $5.63B | $5.02B | $5.59B | $5.49B | $5.07B | 35.4% |
| Other | $1.41B | $1.36B | $0 | $0 | $0 | 0% |
| Total revenue | $17.89B | $16.26B | $15.43B | $14.74B | $14.3B | 100% |
Revenue by region
Where Viatris Inc. generates its revenue.
- Developed Markets60%
- Greater China16%
- Emerging Markets16%
- Japan, Australia and New Zealand8%
- Other< 1%
“Other” combines smaller regions with revenue the company does not assign to a region.
Figures as a table
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|---|---|
| Developed Markets | $8.51B | $10.43B | $9.77B | $9.25B | $8.96B | $8.55B | 59.8% |
| Greater China | $259.9M | $2.21B | $2.2B | $2.16B | $2.17B | $2.33B | 16.3% |
| Emerging Markets | $1.85B | $3.14B | $2.62B | $2.55B | $2.26B | $2.22B | 15.5% |
| Japan, Australia and New Zealand | $1.2B | $2.03B | $1.63B | $1.42B | $1.35B | $1.2B | 8.4% |
| Other | $126.1M | $0 | $0 | $0 | $0 | $0 | 0% |
| Total revenue | $11.95B | $17.89B | $16.26B | $15.43B | $14.74B | $14.3B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 18 Oct 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.